Estrella Immunopharma, Inc. (ESLA): Nasdaq/NYSE listing notice — Estrella Immunopharma receives Nasdaq bid price deficiency notice; faces potential delisting

Estrella Immunopharma, Inc.

Nasdaq notified Estrella that common stock failed to maintain $1.00 minimum bid for 30 consecutive days through April 28, 2025.
Company has 180-day compliance period (until October 27, 2025) to regain compliance with Bid Price Rule.
If not compliant by October 27, may seek additional 180-day period if it meets other listing standards.
No immediate effect on listing; common stock and warrants continue trading on Nasdaq under ESLA and ESLAW.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Estrella Immunopharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

April 28, 2025, the common stock of the Company had not maintained a minimum closing bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until April 30, 2024 (the “Compliance Period”), to regain compliance with the Bid Price Rule. If the Company does not regain compliance with the Bid Price Rule by October 27, 2025, the Company may be eligible for an additional 180-day period to

View on SEC.gov

Browse all listing & compliance notices →

Estrella Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-039261

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.